TGTX

63.3402.37%
YE

Yann Echelard

Independent Director

Dr. Yann Echelard, Ph.D., serves as the President of Ampersand Biomedicines Inc. He serves as Director at Pillar Biosciences Inc. from September 2026. He serves as Managing Partner at ORI Capital. He joined the firm in 2026. He serves as an Operating Partner at Flagship Pioneering, Inc. He joined the company in 2018 focusing on Internal Biotechnology innovation and venture creation. He has been an Independent Director at TG Therapeutics, Inc. since November 2012. He was the Chief Executive Officer and President of rEVO Biologics, Inc. at LFB S.A. from January of 2013 to 2018. Dr. Echelard has several years of research and biopharmaceutical experience. As a visiting scientist at the Roche Institute and at Harvard University (Developmental Biology), Dr. Echelard had a key role in the isolation and characterization of the Hedgehog genes, the first identified vertebrate morphogens. After initial postdoctoral training in oncology at the Ludwig Institute Montreal branch (McGill University), he was a visiting scientist in the laboratory. In addition to his role at rEVO and LFB, Yann was also engaged in spinning-out several companies out of the LFB group, such as Hema Biologics, LFB-USA and Therapeutics. From 1994 to 2010, he progressed through various positions of increased responsibility at Genzyme Transgenics Corporation and at GTC Biotherapeutics, including Vice President of Research and Development. He was initially involved with technology development leading to the commercial application of somatic cell nuclear transfer technology in large animals and to the regulatory approval of ATryn?, the first transgenically-derived therapeutic. In 1998, he led the scientific team that first performed goat somatic cell nuclear transfer (cloning). Focusing on Corporate Development, Dr. Echelard spearheaded the creation of a collaborative Joint Venture with LFB Biotechnologies in 2006, which was focused on the development of recombinant plasma proteins and monoclonal antibodies. He has successively acted as founding President of Ring Therapeutics, Inc., Cellarity Inc., Laronde, Inc. He was a Director at rEVO Biologics, Inc. since May 2012. He has several years of experience across biotechnology and biopharmaceuticals, covering research, clinical development, manufacturing, corporate development and commercial management. Dr. Echelard holds a Ph.D. from Universite de Montreal and has completed post-doctoral training at Ludwig Institute of Cancer Research in Montreal (McGill University) in the year 1989.

Positions